Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenothiazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 10/20 | 0.77 |
| ▸ | MAPT | P10636 | 8/20 | 0.77 |
| ▸ | GAA | P10253 | 7/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | SNCA | P37840 | 3/20 | 0.77 |
| ▸ | BCHE | P06276 | 2/20 | 0.77 |
| ▸ | ACHE | P22303 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.77 |
| ▸ | MAOA | P21397 | 1/20 | 0.77 |
| ▸ | CNR1 | P21554 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.77 |
| ▸ | HTR2C | P28335 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenothiazine SCHEMBL27875754 | 0.98 | NOX1 (0.74) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL3240520 | 0.90 | NOX1 (0.68) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL2504207 | 0.88 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL29352248 | 0.88 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL29349533 | 0.88 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL9114 | 0.88 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL6315328 | 0.88 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL23683396 | 0.85 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL22467847 | 0.85 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL21635186 | 0.85 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4358947-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | UNIVERSITE DE BORDEAUX (FR) | 2024-05-01 | — | — | EP | claimed |
| CN-117897147-A | Combination comprising at least one serotonin reuptake inhibitor and at least one potassium chloride type 2 cotransporter stimulator and medical use thereof | 波尔多大学 | 2024-04-16 | — | — | CN | claimed |
| WO-2023073054-A1 | COMPOSITIONS AND METHODS USING AN AUTOPHAGY INDUCER TO ENHANCE INTERMITTENT FASTING | Société des Produits Nestlé S.A. (CH) | 2023-05-04 | — | — | WO | claimed |
| WO-2022268738-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | Universite de Bordeaux (FR) | 2022-12-29 | — | — | WO | claimed |
| EP-4108238-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | UNIVERSITE DE BORDEAUX (FR) | 2022-12-28 | — | — | EP | claimed |
| WO-2021116611-A1 | FORMULATION FOR METHYLENE BLUE AND METHOD | Universite de Bordeaux (FR) | 2021-06-17 | — | — | WO | claimed |
| CN-101400350-A | Serotonergic agents for treating sexual dysfunction | WYETH CORP (US) | 2009-04-01 | — | — | CN | claimed |
| EP-1971337-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | Wyeth a Corporation of the State of Delaware (US) | 2008-09-24 | — | — | EP | claimed |
| WO-2007137224-A2 | METHOD OF TREATMENT | VANDA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007081374-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | WYETH (US) | 2007-07-19 | — | — | WO | claimed |
| US-20060287335-A1 | Serotonergic agents for treating sexual dysfunction | WYETH (US) | 2006-12-21 | — | — | US | claimed |
| WO-2004096231-A2 | USE OF PIPERAZINE PHENOTHIAZINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT WITH NEUROPROTECTOR AND/OR NEUROTROPHIC EFFECTS ON CNS AND/OR PNS | NEURO 3D (FR) | 2004-11-11 | — | — | WO | claimed |
| EP-1470818-A1 | Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns | NEURO3D (FR) | 2004-10-27 | — | — | EP | claimed |
| US-20240197728-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | INST NAT SANTE RECH MED (FR) | 2024-06-20 | — | — | US | disclosed |
| WO-2024099883-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | Société des Produits Nestlé S.A. (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024099886-A1 | THYMOL OR CARVACROL FOR USE IN REDUCING THE BIOLOGICAL AGE OR OF THE RATE OF ITS INCREASE | Société des Produits Nestlé S.A. (CH) | 2024-05-16 | — | — | WO | disclosed |
| US-5786344-A | ADMINISTERING WITH AGENT WHICH INCREASES ACTIVITY OF GLUCURONOSYLTRANSFERASE OR DECREASES ACTIVITY OF BILIARY TRANSPORT PROTEIN | ARCH DEVELOPMENT CORPORATION (US) | 1998-07-28 | — | — | US | disclosed |
| EP-0768895-A1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001127-A1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 1996-01-18 | — | — | WO | disclosed |
| US-4758562-A | Method for inducing hypothermia and/or poikilothermia | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1988-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287335-A1 | Serotonergic agents for treating sexual dysfunction | HTR5A, HTR1A, HTR3A | NOX1 3956/4885MAPT 1722/4885GAA 2338/4885 |
| US-20240197728-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | SLC6A13, SLC6A1, CLCN2 | NOX1 4634/4885MAPT 1619/4885GAA 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.